MeiraGTx (MGTX)

Executive Summary

MeiraGTx (NASDAQ: MGTX) is a clinical-stage genetic medicine company developing gene therapies for inherited retinal diseases, neurodegenerative disorders, and other serious conditions. The company leverages adeno-associated virus (AAV) vectors to deliver functional genes to target cells, aiming to provide durable or curative treatments. MeiraGTx's pipeline includes seven investigational candidates, with lead programs in achromatopsia (AAV-CNGB3, AAV-CNGA3), Leber congenital amaurosis (AAV-RPE65), and radiation-induced xerostomia (AAV2hAQP1). Phase 1/2 trials for the retinal candidates have been completed, demonstrating safety and early efficacy signals. The most advanced active trial is AAV2hAQP1 for xerostomia in head and neck cancer patients, with completion expected in mid-2026. MeiraGTx also has preclinical programs in neurodegenerative diseases, including Parkinson's disease. The company has raised significant capital through public offerings and partnerships to support its clinical development and manufacturing capabilities. With a strong focus on rare genetic disorders, MeiraGTx positions itself as a leader in the gene therapy space, though its valuation remains tied to clinical data readouts and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026AAV2hAQP1 Phase 1 Clinical Data for Radiation-Induced Xerostomia65% success
• TBDRegulatory Update on Retinal Gene Therapy Programs (Achromatopsia or LCA)40% success